China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche
But Can China Take As Many As Eight More?
Executive Summary
Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.
You may also be interested in...
AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.
Paradox Of China Biotech And What Lies Ahead In 2023
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.